Digital twins and virtual trials: A new era in rare disease drug development

The article “Digital Twins and Virtual Trials: A New Era in Rare Disease Drug Development” discusses how these advanced simulation technologies are transforming rare disease drug development. Digital twins refer to virtual representations of patients. They enable precise modeling of real-world responses to medicines, reducing reliance on traditional control groups and large patient populations. Virtual trials further enhance this by simulating the impacts of drugs across diverse scenarios. Leveraging these technologies not only expedites therapy development, but also drives personalized medicine, addressing underserved populations more effectively. The integration of AI-based modeling promises to revolutionize clinical trials, saving time and costs, while accelerating life-changing discoveries.